Creating a Global Company

Research & Development Cumulative R&D Spend of ~Rs. 209 billion to date R&D Spend • . Capabilities Organization R&D spend at 6.5% of sales for FY21 Strong cash flows & large scale to support R&D investments Capabilities in finished dosage development, biological support, chemistry and new drug development • Approx. 2,700 headcount globally with capabilities across dosage forms like orals, liquids, ointments, gels, sprays, injectables IPR Support . Focus Strong team of intellectual property experts supporting R&D • Developing non infringing formulations and development of specialty/complex products SUN PHARMA 38

View entire presentation